Across TCGA pan-cancer cohorts, TRAPPC2P9 RNA is linked to patient survival in 1 of 34 cancer types, making it the most broadly survival-associated TRAPPC2P9 data layer.
The strongest signal is observed in stomach adenocarcinoma (STAD), where higher TRAPPC2P9 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated TRAPPC2P9 expression acts as an unfavorable survival marker.
STAD are the cancer types where TRAPPC2P9 RNA most reproducibly stratifies survival.